@article{oai:kanazawa-u.repo.nii.ac.jp:00014353,
 author = {Takamatsu, Hiroyuki and Araki, Raita and Nishimura, Ryosei and Yachie, Akihiro and Espinoza, J. Luis and Okumura, Hirokazu and Yoshida, Takashi and Kuzushima, Kiyotaka and Nakao, Shinji},
 journal = {Journal of Clinical Virology},
 month = {Jun},
 note = {Leukemic Epstein-Barr virus (EBV)-associated post-transplant lymphoproliferative diseases (PTLD) following allogeneic hematopoietic stem cell transplantation are extremely rare. We can successfully treat an EBV-associated leukemic lymphoma patient with rituximab, cidofovir, and donor lymphocyte infusion (DLI). In the present case, EBV-specific T cells that were present in the peripheral blood before rituximab administration treatment rapidly increased after DLI in association with a decrease in the EBV-DNA load. © 2016 Elsevier B.V., Embargo Period 12 months},
 pages = {82--86},
 title = {Epstein-Barr virus-associated leukemic lymphoma after allogeneic stem cell transplantation},
 volume = {80},
 year = {2016}
}